Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors
    • Author Guidelines
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • 20th Anniversary Special Edition
    • Topic/Program Collections
    • Blog
    • Questions from NeoReviews
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
    • NeoReviewsPlus
    • Board Review Study Guide
  • Multimedia
    • NeoReviews Video Library
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors
    • Author Guidelines
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • 20th Anniversary Special Edition
    • Topic/Program Collections
    • Blog
    • Questions from NeoReviews
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
    • NeoReviewsPlus
    • Board Review Study Guide
  • Multimedia
    • NeoReviews Video Library
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Article

Pharmacology Review

Intravenous Ibuprofen for Preterm Newborns

J. V. Aranda and Ronald Thomas
NeoReviews November 2005, 6 (11) e516-e523; DOI: https://doi.org/10.1542/neo.6-11-e516
J. V. Aranda
*Pediatric Pharmacology Research Unit Network, Division of Clinical Pharmacology and Toxicology, Children’s Hospital of Michigan, Detroit, Mich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Thomas
*Pediatric Pharmacology Research Unit Network, Division of Clinical Pharmacology and Toxicology, Children’s Hospital of Michigan, Detroit, Mich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Introduction

Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is a chiral compound derived from arylproprionic acid. It is used widely as an antipyretic, anti-inflammatory, and analgesic agent and for therapy of arthritis. It was approved by the United States Food and Drug Administration in 1974 and later became available as an over-the-counter drug. In 1979, Cocceani and associates (1) demonstrated a dose-dependent constriction of the ductus arteriosus caused by ibuprofen in newborn lambs. Its current use in human newborns was stimulated by its demonstrated improvement of cerebral blood flow (CBF) autoregulation in newborn animals (2) and its potential to offer some degree of neuroprotection. In contrast to indomethacin, ibuprofen did not decrease and impair regional blood flow to the brain in newborn infants and animals. (3)

In addition to neuroprotection, ibuprofen also may close the patent ductus arteriosus (PDA) in newborn humans, as has been shown in newborn lambs. A pilot study published in 1996 suggested that, compared with placebo, intravenous (IV) ibuprofen closed the PDA and shortened the hospital stay in preterm newborns with minimal renal adverse effects. (4) The development of two IV formulations of ibuprofen (ibuprofen lysine and ibuprofen THAM) permitted evaluation of this drug in preterm newborns. To date, efficacy, safety, dose finding, pharmacokinetic, and pharmacodynamic data in the newborn indicate that this drug is effective for ductal closure in preterm neonates. Data on safety depend on the formulation studied. (5)(6) This review examines the published data on ibuprofen up to June 2005 and concludes that ibuprofen lysine is a safe and effective drug for PDA closure in newborns.

Clinical Studies

More than 20 clinical trials have compared IV ibuprofen with placebo or indomethacin; others have evaluated the pharmacodynamic effects of the drug before and after its administration. Compared with placebo, IV ibuprofen decreased PDA, with little …

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

NeoReviews
Vol. 6, Issue 11
1 Nov 2005
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacology Review
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Pharmacology Review
J. V. Aranda, Ronald Thomas
NeoReviews Nov 2005, 6 (11) e516-e523; DOI: 10.1542/neo.6-11-e516

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pharmacology Review
J. V. Aranda, Ronald Thomas
NeoReviews Nov 2005, 6 (11) e516-e523; DOI: 10.1542/neo.6-11-e516
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Introduction
    • Clinical Studies
    • Ibuprofen Lysine or Ibuprofen THAM Versus Placebo
    • Ibuprofen Versus Indomethacin
    • IV Ibuprofen Pharmacodynamics
    • Oral Ibuprofen
    • Meta-Analyses
    • Efficacy in IVH
    • Dose Finding
    • Pharmacokinetics, Metabolism, and Disposition
    • Adverse Effects and Potential Interaction
    • Summary
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments

Related Articles

  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Craniosynostosis: Neonatal Perspectives
  • Congenital Hyperinsulinism
  • Revisiting Skeletal Dysplasias in the Newborn
Show more Articles

Similar Articles

Subjects

  • Pharmacology
    • Pharmacology
  • Fetus/Newborn Infant
    • Fetus/Newborn Infant
  • Journal Info
  • Editorial Board
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • NeoReviewsPlus
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
  • NeoReviews™ and NeoReviewsPlus™ are supported, in part, through an educational grant from Abbott Nutrition, a division of Abbott Laboratories, Inc.
American Academy of Pediatrics

© 2021 American Academy of Pediatrics